Saccharomyces cerevisiae var. boulardii VSL

Saccharomyces cerevisiae var. boulardii VSL is a probiotic yeast strain that produces bioactive metabolites including capric acid and caprylic acid with demonstrated antifungal activity against Candida albicans in vitro. Its primary mechanisms involve disruption of fungal cell membranes, bile salt tolerance enabling gastrointestinal survival, and modulation of tryptophan catabolism pathways to influence immune signaling.

Origin & History

Saccharomyces cerevisiae var. boulardii VSL is a specific probiotic yeast strain distinguished by unique genetic markers including microsatellite polymorphisms in genes YKL139w and YLR177w. Originally isolated in the 1920s by Henri Boulard from tropical fruit peels (lychee and mangosteen) in Indochina, it is now cultivated via fermentation in nutrient media for 5-7 days.

Historical & Cultural Context

Isolated in the 1920s by Henri Boulard from lychee and mangosteen peels in Indochina, where locals traditionally chewed fruit skins or made tea to prevent cholera symptoms. No evidence of use in established traditional medicine systems like Ayurveda or TCM was found.

Health Benefits

• Antifungal activity against Candida albicans through bioactive compounds (preliminary evidence from in vitro studies)
• Enhanced gut survival due to bile tolerance up to 2.5% and pH 4 resistance (preliminary in vitro evidence)
• Potential immunomodulatory effects via altered tryptophan catabolism pathways (preliminary genetic analysis)
• Thermotolerance at body temperature (37°C) for optimal gut colonization (preliminary laboratory evidence)
• Note: No human clinical trials specific to VSL strain were found in the research

How It Works

Saccharomyces cerevisiae var. boulardii VSL exerts antifungal effects primarily through secreted bioactive lipid compounds, including medium-chain fatty acids such as capric acid, which disrupt Candida albicans cell membrane integrity by targeting phospholipid bilayer organization. The strain's resistance to bile concentrations up to 2.5% and low pH environments (pH 4) is attributed to membrane ergosterol composition and active proton pump activity, enabling colonization of the lower gastrointestinal tract. Additionally, the strain alters tryptophan catabolism by influencing indole pathway metabolites, which interact with aryl hydrocarbon receptors (AhR) on intestinal immune cells to modulate cytokine production and regulatory T-cell activity.

Scientific Research

The research dossier contains no human clinical trials, RCTs, or meta-analyses specifically for the VSL strain. Molecular differentiation studies involving 35 isolates (27 clinical, 8 probiotic) confirmed strain identity via PCR-restriction and microsatellite analysis, while in vitro studies demonstrated probiotic attributes including bile tolerance and pH resistance.

Clinical Summary

Current evidence for Saccharomyces cerevisiae var. boulardii VSL is predominantly derived from in vitro laboratory studies rather than randomized controlled trials, limiting the strength of clinical conclusions. In vitro studies have demonstrated dose-dependent inhibition of Candida albicans growth and confirmed bile tolerance up to 2.5% and acid stability at pH 4, suggesting theoretical gastrointestinal viability in humans. Immunomodulatory effects via tryptophan-AhR signaling have been characterized in cell-based assays but have not yet been validated in human clinical trials with measurable patient outcomes. No large-scale human studies with defined sample sizes or quantified clinical endpoints have been published specifically for this VSL designator strain, and all benefits should be considered preliminary pending controlled human trials.

Nutritional Profile

Saccharomyces cerevisiae var. boulardii VSL is a probiotic yeast strain with a nutritional and bioactive profile characteristic of Saccharomyces boulardii lineage with strain-specific modifications. Key components include: Protein content approximately 40-50% of dry cell weight, composed of all essential amino acids with notable concentrations of glutamic acid, aspartic acid, and leucine. Cell wall polysaccharides constitute approximately 15-30% dry weight, predominantly beta-1,3/1,6-glucans (estimated 10-15% dry weight) and mannoproteins (estimated 5-10% dry weight), both recognized as immunomodulatory bioactive compounds. Chitin comprises approximately 1-3% of dry cell wall mass. B-vitamin content includes thiamine (B1) approximately 1-2 mg per 100g dry weight, riboflavin (B2) approximately 3-5 mg per 100g dry weight, niacin (B3) approximately 30-50 mg per 100g dry weight, pantothenic acid (B5) approximately 10-15 mg per 100g dry weight, pyridoxine (B6) approximately 2-4 mg per 100g dry weight, and folate approximately 1-2 mg per 100g dry weight; bioavailability of these B-vitamins from whole yeast cells is estimated at 60-80% due to partial cell wall digestion in the gut. Mineral content includes zinc approximately 5-10 mg per 100g dry weight, selenium approximately 0.1-0.3 mg per 100g dry weight (strain-dependent), chromium in trace amounts, and magnesium approximately 50-80 mg per 100g dry weight. Ergosterol (provitamin D2 precursor) is present at approximately 0.5-1.5% dry weight. Bioactive tryptophan catabolism metabolites including indole derivatives and kynurenine pathway intermediates are produced during metabolic activity, concentrations dependent on substrate availability; the VSL designation suggests optimized production of these immunomodulatory tryptophan metabolites per preliminary genetic analysis. Polyunsaturated fatty acids including oleic acid and linoleic acid are present in the lipid fraction (approximately 2-5% dry weight total lipids). Trehalose as a stress-protective disaccharide is present at approximately 5-15% dry weight and contributes to thermotolerance at 37°C. Antifungal bioactive compounds, likely including cell wall-associated proteins and secreted peptides active against Candida albicans, are produced in culture but specific concentrations in final probiotic preparations are not yet quantified in published literature. Viable cell counts in commercial preparations typically range from 1×10^9 to 1×10^10 CFU per gram. Bioavailability of intact cells to the lower GI tract is supported by demonstrated bile tolerance up to 2.5% and pH 4 resistance, suggesting a meaningful proportion of ingested cells reach the colon viable.

Preparation & Dosage

No clinically studied dosage ranges are available for the VSL strain specifically. General S. boulardii use lacks standardization details in the provided research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, prebiotics (FOS/inulin), vitamin D, zinc, digestive enzymes

Safety & Interactions

Saccharomyces boulardii strains are generally well-tolerated in healthy adults at doses of 250–500 mg daily, with the most common adverse effects being mild bloating and flatulence. Immunocompromised individuals, those with central venous catheters, or patients with systemic fungal susceptibility face a rare but documented risk of fungemia, and this strain is contraindicated in such populations. Saccharomyces boulardii may reduce the efficacy of antifungal medications such as fluconazole if used concurrently, and concurrent use with broad-spectrum antifungals may compromise probiotic viability. Safety data in pregnant or lactating women is insufficient for this specific VSL variant, and use during pregnancy should be discussed with a healthcare provider before initiation.